FindTrial
Sign In

Investigation of outcomes with implementation of CYP2C19 genotype- and clinical characteristics-guided antiplatelet therapy after percutaneous coronary intervention: a case records based study

Investigation of outcomes with implementation of CYP2C19 genotype- and clinical characteristics-guided antiplatelet therapy after percutaneous coronary intervention: a case records based study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022547
Enrollment
Unknown
Registered
2019-04-16
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Genetic testing group:Genetic test of CYP2C19
Control group:No genetic test of CYP2C19

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Undergoing PCI with stent implantation for ACS or stable coronary heart disease; 2. Sufficient clinical information, including the patient's basic characteristics and treatment information; 3. Planing to receive DAPT treatment for 1 year after procedure.

Exclusion criteria

Exclusion criteria: 1. History of atrial fibrillation, valvular disease and indications to the use of other oral anticoagulant; 2. Any contraindication to the use of P2Y12 receptor antagonist; 3. A life expectancy of <1 year ; 4. Prior knowledge of the patients' CYP2C19 genotype.

Design outcomes

Primary

MeasureTime frame
Major cardiovascular adverse event;—

Secondary

MeasureTime frame
Bleeding event (BARC class 3 to 5 bleeding event);—

Countries

China

Contacts

Public ContactWei Liu

Beijing Anzhen Hospital, Capital Medical University

liuwei@ccmu.edu.cn+86 18910938225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026